The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACELYRIN INC COM 00445A100   39,179,620 3,852,470 SH   SOLE   3,852,470 0 0
ALX ONCOLOGY HLDGS INC COM 00166B105   46,559,640 9,699,925 SH   SOLE   9,699,925 0 0
ELEVATION ONCOLOGY INC COM 28623U101   1,930,985 2,914,255 SH   SOLE   2,914,255 0 0
HARMONY BIOSCIENCES HLDGS IN COM 413197104   33,929,927 1,035,396 SH   SOLE   1,035,396 0 0
IMPEL PHARMACEUTICALS INC COM 45258K109   1,186,710 2,759,791 SH   SOLE   2,759,791 0 0
PHARVARIS N V COM N69605108   89,003,705 4,264,672 SH   SOLE   4,264,672 0 0
RAYZEBIO INC COM 75525N107   114,511,196 5,158,162 SH   SOLE   5,158,162 0 0
VENTYX BIOSCIENCES INC COM 92332V107   26,353,124 758,800 SH   SOLE   758,800 0 0